Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.

This study has been terminated.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: August 31, 2005
Last updated: February 15, 2012
Last verified: February 2012

August 31, 2005
February 15, 2012
March 2005
December 2006   (final data collection date for primary outcome measure)
Change in LDL-C and non-HDL-C levels.
Same as current
Complete list of historical versions of study NCT00145431 on Archive Site
Changes in other lipid and biomarker variable levels.
Same as current
Not Provided
Not Provided
Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.
Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia).

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

To evaluate the efficacy and safety of the lipid drug torcetrapib/atorvastatin in subjects with a rare genetically known disorder of high cholesterol and triglyceride levels.

For additional information please call: 1-800-718-1021
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Hyperlipoproteinemia Type III
  • Drug: torcetrapib/atorvastatin
  • Drug: atorvastatin
  • Drug: fenofibrate
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
December 2006
December 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of Familial Dysbetalipoproteinemia (Fredrickson Type III hyperlipoproteinemia)

Exclusion Criteria:

  • Women who are pregnant or lactating, or planning to become pregnant.
  • Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid
  • Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
  • Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
Not Provided
Not Provided
Not Provided
Not Provided
Study Director: Pfizer Call Center Pfizer
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP